MCRB
Seres Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.72
+1.42%Aug 5, 2026, 11:00 UTC
Seres Therapeutics announced an agreement to exit additional leased space early to reduce ongoing facility-related cash costs, following earlier balance sheet strengthening and facilities cost reduction transactions in June 2026.
Source:Aug 5, 2026, 11:00 UTC
Seres Therapeutics reported its second quarter 2026 financial results and provided business updates on August 5, 2026.
Source:Aug 5, 2026, 00:00 UTC
Seres Therapeutics received a $25 million milestone termination payment from Nestlé related to the sale of the VOWST business, with the first installment of $12.5 million received and the second installment of $12.5 million to be received.
Jul 8, 2026, 17:07 UTC
Seres Therapeutics Inc. reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis, with most participants achieving a steroid-free clinical response.
Source:Jun 8, 2026, 01:54 UTC
Seres Therapeutics restructured the lease for its facility at 101 CambridgePark Drive in Cambridge, Massachusetts, reducing space, rental rates, and operating expenses.
Source:Jun 8, 2026, 01:54 UTC
Seres Therapeutics entered into an agreement with Nestlé Health Science to receive $25 million in 2026 in exchange for buying out future milestone payments related to VOWST.
Source:Jun 5, 2026, 00:00 UTC
Seres Therapeutics amended an asset purchase agreement with Société des Produits Nestlé S.A., terminating contingent milestone payments in exchange for a $25 million termination payment.
Source:Jun 1, 2026, 00:00 UTC
Hans-Juergen Woerle, M.D., Ph.D. resigned as a member of the board of directors of Seres Therapeutics, Inc., effective May 31, 2026.